EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer`s Disease Samantha Budd Haeberlein,1 Christian von Hehn,1 Ying Tian,1 Spyros Chalkias,1 Kumar Kandadi Muralidharan,1 Tianle Chen,1 Shuang Wu,1 Jie Li,1 LeAnne Skordos,1 Laura Nisenbaum,1 Raj Rajagovindan,1 Gersham Dent,1 Katie Harrison,1 Ivan Nestorov,1 Ying Zhu,1 Craig Mallinckrodt,1 Alfred Sandrock1 1Biogen, Cambridge, MA, USA Disclosures: SBH (presenter), CvH, YT, SC, KKM, TC, SW, JL, LS, LN, RR, GD, KH, IN, YZ, CM, and AS are employees Biogen 1 Forward-looking statements This presentation contains forward-looking statements, including statements made pursuant to the safe harbor...
|
